Localised Scleroderma Morphoea

Authored by , Reviewed by Dr John Cox | Last edited | Meets Patient’s editorial guidelines

This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Localised Scleroderma (Morphoea) article more useful, or one of our other health articles.

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Localised scleroderma, also called morphoea or morphea, is a disorder of excessive collagen deposition leading to thickening of the dermis and sometimes the subcutaneous tissues. The word scleroderma means 'hard skin' and in localised scleroderma, fat, fascia, muscle and bone may also be affected but not internal organs as in systemic scleroderma. See the separate Systemic Sclerosis (Scleroderma) article.

Localised scleroderma is an uncommon condition where the affected person has areas of thickened skin. Studies of incidence and prevalence are inadequate; the actual numbers are likely to be far higher because many cases may not come to medical attention. However, a relatively recent study reports incidence in children (under the age of 16 years) in the UK and Ireland to be 3.4 per million per year.[1]

Up to half of all cases occur in children. Prevalence is similar in adults and children; however, children are 90% more likely to have localised scleroderma than the systemic disease.[2] The most common age of disease onset in children is 5-10 years.[1, 3] Peak incidence in adults is in the 5th decade.[2] Women are at least twice as likely as men to be affected.[4] When acquired in childhood, the disease tends to take a more severe form.[5]

The cause of localised scleroderma is unknown. It is thought that a genetic predisposition may lead to an immunologically mediated cytokine release, causing inflammation, dysfunction of the connective tissue metabolism and subsequent fibrosis[6] . It appears to be debatable whether there is any risk of progression to systemic sclerosis; however, although the pathogenesis is similar, it is probably a completely separate disease.[7, 8]

In some cases it has been thought to follow:[4]

  • Tick bites - it has been associated with Lyme disease.
  • Measles and other viral infections.
  • Localised injury.
  • Pregnancy.
  • Autoimmune diseases, including vitiligo, diabetes, lichen sclerosus and lichen planus.
  • Radiotherapy. It may be as common as 2 in every 1,000 patients treated with radiotherapy.[9]

A few familial cases have been reported. People with localised scleroderma tend to have a family history of autoimmune disease.[8]

Plaque morphoea

This is the most common type of morphoea:

  • Plaques are thickened, usually oval patches of skin between 1-20 cm (or greater) in diameter.
  • They start as a mauve colour, then change to ivory white in the middle with a lilac edge over several months. Long-standing plaques may be brown.
  • Their surface is hairless, smooth and shiny. They tend not to sweat. Several asymmetrical plaques may be present on both sides of the trunk and limbs.
  • Sometimes the surface is hyperpigmented with very little to feel.
Morphoea small

Superficial morphoea

  • Middle-aged women usually present with symmetrical mauve-coloured patches in the skin folds.
  • They are particularly common in the groin, armpits and under the breasts.

Linear morphoea

This is the most common form in children:

  • It may present on the scalp/forehead and limbs. This is most often found on the limb of a child.
  • A long and narrow plaque may be associated with underlying contractures.
  • A deep form affecting the scalp is called 'en coup de sabre' - a sabre cut. The hair is lost permanently and the underlying skull bone may shrink.

Pansclerotic disabling morphoea

This is rare:

  • It affects children and results in extensive hardening of skin and underlying muscle.
  • The growth of bones may be affected.
  • It can lead to joint contractures, non-healing ulcers and squamous cell carcinoma.

Generalised morphoea

  • Four or more plaques affecting two or more body regions. There may be widespread skin thickening over the trunk.

Parry-Romberg syndrome

This is a rare neurocutaneous disorder:

  • Linear scleroderma is associated with progressive facial hemiatrophy, migraine, facial pain and epilepsy.[10]

Atrophoderma of Pierini and Pasini

  • Depression in the skin caused by significant loss of subcutaneous tissue.

It is possible for several types to be present in one patient.

Blood tests have little role in assessment of localised scleroderma, although confirmatory tests are sometimes done to assist in diagnosis. Polyclonal increases in immunoglobulin G and M may occur, especially in patients with linear and deep morphoea. Autoantibodies (eg, rheumatoid factor, antinuclear antibodies) are frequently positive. The autoantibody profile differs from systemic sclerosis (SSc) however. In SSc, the vast majority are positive for anti-nuclear antibody (ANA), whereas this varies from 20-80% in localised scleroderma.[8] The SSc-specific autoantibodies are not usually found in people with localised scleroderma.

Although a presumptive diagnosis can frequently be made on clinical findings, a biopsy can be used to confirm the diagnosis and delineate the depth of involvement:

  • For plaque-type and generalised morphoea, a deep punch biopsy (including subcutaneous fat) is usually sufficient.
  • For linear and deep morphoea, an incisional biopsy extending down to muscle is required.

Radiography may be helpful in cases of linear or deep morphoea where involvement of the underlying bone is suspected. It can also be used to monitor paediatric patients for potential growth defects. Ultrasound is increasingly useful to monitor underlying disease activity.[11]

  • Infiltrating secondary neoplasia is a rare possibility.
  • A white atrophic surface can also be due to lichen sclerosus et atrophicus.
  • Brown pigmentation on the surface is most likely to be due to post-inflammatory hyperpigmentation rather than morphoea.
  • In very young infants, early skin changes may be misdiagnosed as port-wine stains.[12]
  • SSc. (Skin changes associated with Raynaud's phenomenon and other associated vascular and systemic features.)

All suspected cases should be referred for diagnosis.

Unfortunately there is no available, effective treatment for most cases of localised scleroderma. Although several have shown possible benefit in research, few controlled trials have been performed. There is no consensus on optimal treatment. Therapy aimed at reducing inflammatory activity in early disease is more successful than attempts to decrease sclerosis in well-established lesions.[2] Physiotherapy may be helpful to prevent joint contractures in severe disease.

There is evidence for efficacy of the following treatment options:[6, 8]

  • Ultraviolet B (UVB) phototherapy for superficial skin involvement.
  • UVA phototherapy for deeper skin involvement. Efficacy has been proven, although there is no certainty yet about the long-term safety and the risk of skin cancer.[13]
  • Immunosuppression. The best evidence is for methotrexate +/- systemic corticosteroids for involvement of underlying tissues and for rapidly progressive or severe disease. There has been some work to attempt to standardise treatment regimens.[5] Mycophenolate mofetil is used as a second-line agent but the evidence base is less good.
  • Topical tacrolimus.[14]
  • Topical imiquimod.
  • Topical calcipotriol with or without betamethasone diproprionate.

Type of treatment is based on the type of localised scleroderma and its extent - for example:[8]

  • Limited superficial plaque morphoea may respond to topical treatment or local phototherapy.
  • Deep plaque morphoea may require phototherapy or systemic immunosuppression with methotrexate and steroids.
  • Linear morphoea is usually aggressively treated with immunosuppression.
  • Generalised morphoea is usually not suitable for topical therapy, due to the large surface area involved, so phototherapy or immunosuppression is usually required.

Localised scleroderma is rarely life-threatening but may have a significant adverse effect on quality of life, as it can be disfiguring and disabling.

  • Generally the lesions gradually improve over a period of years and may even resolve spontaneously.
  • Plaque-type morphoea is usually active for several years then slowly softens, leaving brown staining and sometimes depressed areas of skin.
  • Linear morphoea tends to be more progressive and lasts longer but also eventually improves, although sometimes deposits of calcium arise within the lesions. It needs monitoring, as there may be reactivation after long dormant periods.[15] There is a high likelihood of cosmetic sequelae.
  • Limbs affected by severe morphoea may be stiff and weak if there is muscle wasting. Growth may be affected and there may be limb length differences and joint contractures
  • Facial atrophy may develop.
  • There may be ocular and neurological sequelae where it presents on the head and neck of children. Neurological complications include seizures, headaches, peripheral neuropathy, vascular malformations, and behavioural changes.
  • Where the condition develops in childhood, it tends to have more of a relapsing and remitting course and to produce more severe lesions than that which arises for the first time in adulthood.[16]

Further reading and references

  1. Herrick AL, Ennis H, Bhushan M, et al; Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010 Feb62(2):213-8. doi: 10.1002/acr.20070.

  2. Careta MF, Romiti R; Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 2015 Jan-Feb90(1):62-73. doi: 10.1590/abd1806-4841.20152890.

  3. Weibel L, Laguda B, Atherton D, et al; Misdiagnosis and delay in referral of children with localized scleroderma. Br J Dermatol. 2011 Dec165(6):1308-13. doi: 10.1111/j.1365-2133.2011.10600.x. Epub 2011 Nov 2.

  4. Morphoea; DermNet NZ

  5. Li SC, Torok KS, Pope E, et al; Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2012 Aug64(8):1175-85. doi: 10.1002/acr.21687.

  6. Kreuter A; Localized scleroderma. Dermatol Ther. 2012 Mar-Apr25(2):135-47. doi: 10.1111/j.1529-8019.2012.01479.x.

  7. Fett NM; Morphea (localized scleroderma). JAMA Dermatol. 2013 Sep149(9):1124. doi: 10.1001/jamadermatol.2013.5079.

  8. Fett N; Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol. 2013 Jul-Aug31(4):432-7. doi: 10.1016/j.clindermatol.2013.01.010.

  9. Alhathlool A, Hein R, Andres C, et al; Post-Irradiation Morphea: Case report and review of the literature. J Dermatol Case Rep. 2012 Sep 286(3):73-7. doi: 10.3315/jdcr.2012.1106.

  10. Maletic J, Tsirka V, Ioannides P, et al; Parry-Romberg Syndrome Associated with Localized Scleroderma. Case Rep Neurol. 2010 Jun 12(2):57-62.

  11. Zulian F, Cuffaro G, Sperotto F; Scleroderma in children: an update. Curr Opin Rheumatol. 2013 Sep25(5):643-50. doi: 10.1097/BOR.0b013e3283641f61.

  12. Kanoh H, Shu E, Ichiki Y, et al; Localized scleroderma presenting as port-wine stains: report of two cases and a literature review. Acta Derm Venereol. 2015 Nov95(8):1003-4. doi: 10.2340/00015555-2100.

  13. Kerr AC, Ferguson J, Attili SK, et al; Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report. Clin Exp Dermatol. 2012 Apr37(3):219-26. doi: 10.1111/j.1365-2230.2011.04256.x. Epub 2012 Jan 25.

  14. Cantisani C, Miraglia E, Richetta AG, et al; Generalized morphea successfully treated with tacrolimus 0.1% ointment. J Drugs Dermatol. 2013 Jan12(1):14-5.

  15. Piram M, McCuaig C, Saint-Cyr C, et al; Short And Long Term Outcome Of Linear Morphea In Children. Br J Dermatol. 2013 Sep 6. doi: 10.1111/bjd.12606.

  16. Saxton-Daniels S, Jacobe HT; An evaluation of long-term outcomes in adults with pediatric-onset morphea. Arch Dermatol. 2010 Sep146(9):1044-5.